登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Medical Hypotheses，6月27日，Rethinking interleukin-6 blockade for treatment of COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-06-28

  • Rethinking interleukin-6 blockade for treatment of COVID-19
    Author links open overlay panelS.SchergeraA.Henao MartinezaC.Franco-ParedesaL.Shapiroabc
    Show more
    https://doi.org/10.1016/j.mehy.2020.110053

    Abstract
    Interleukin-6 (IL-6) is a pleiotropic cytokine with effects in immune regulation, inflammation, and infection. The use of drugs that inhibit IL-6 biological activity has been proposed as a treatment for patients with Coronavirus Disease 2019 (COVID-19). The rationale for this approach includes commitment to the concept that inflammation is a cause of lung damage in COVID-19 and belief that IL-6 is a pro-inflammatory molecule. Observational data thought to support IL-6 inhibition include elevated circulating IL-6 levels in COVID-19 patients and association between elevated IL-6 and poor clinical outcomes. However, IL-6 has significant anti-inflammatory properties, which calls into question the rationale for employing IL-6 blockade to suppress inflammation-induced tissue injury. Also, studies suggesting a beneficial role for IL-6 in the host response to infection challenge the strategy of using IL-6 blockade to treat COVID-19.

  • 原文来源：https://www.sciencedirect.com/science/article/abs/pii/S0306987720310653
50浏览量
原文链接
相关报告

  • 《6月27日_白介素-6阻断剂治疗COVID-19的作用》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-29
    • 信息名称：白介素-6阻断剂治疗COVID-19的作用 1.时间：2020年6月27日 2.机构或团队：科罗拉多大学丹佛分校、落基山地区退伍军人事务医疗中心、艾米丽医学研究基金会 3.事件概要： 科罗拉多大学丹佛分校等机构在Medical Hypotheses发表论文“Rethinking interleukin-6 blockade for treatment of COVID-19”。 白介素-6（IL-6）是一种多效细胞因子，在免疫调节、炎症和感染中发挥作用。使用抑制IL-6生物活性的药物已被建议用于2019冠状病毒病（COVID-19）患者的治疗，因为炎症被认为是COVID-19肺损伤的原因，以及IL-6是一种促炎分子。然而，IL-6又具有显著的抗炎特性，这就对使用IL-6抑制炎症性组织损伤的原理提出了质疑。此外，研究表明IL-6在宿主对感染的应答中发挥有益作用。在向人类志愿者注射重组IL-6的研究中，观察到IL-6水平超过COVID-19患者的水平，但没有出现肺不良事件或其他器官损害。IL-6受体拮抗剂（如tocilizumab）的临床经验表明，严重感染和机会性感染增加，这引起了人们对使用tocilizumab和类似药物治疗COVID-19的担忧。IL-6抑制剂在COVID-19中药物试验正在进行中，这将阐明IL-6在COVID-19发病机制中的作用。然而，在获得更多的信息之前，医生在开处方时应该谨慎对待这些疗法，因为这可能会对病人造成伤害。 4.附件： 原文链接：https://www.sciencedirect.com/science/article/abs/pii/S0306987720310653
    37浏览量
    原文链接

  • 《Oral Oncology，3月21日，New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-22
    • New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws Author links open overlay panelFrancescoBennardoCaterinaBuffoneAmerigoGiudice Show more https://doi.org/10.1016/j.oraloncology.2020.104659 To the Editor A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2; previously known as 2019-nCoV) emerged in Wuhan (Hubei, China) in December 2019 and spread rapidly across the planet. Several coronaviruses can cause light respiratory disease in humans but SARS-CoV-2 can cause a pneumonia, called corona virus disease-2019 (COVID-19) that might result in death due to massive alveolar damage and progressive respiratory failure [1]. Similarly to the “SARS-CoV” (emerged in 2003) and “MERS-CoV” (emerged in 2012), SARS-CoV-2 was probably hosted by bat and transmitted from other animals to humans [2]. The World Health Organization declared COVID-19 pandemic on March 12, 2020 [3].
    14浏览量
    原文链接